Loading...
Loading...
Rigel
Pharmaceuticals, Inc.
RIGL today announced that R343, an inhaled SYK
inhibitor being evaluated as a potential therapeutic for patients with
allergic asthma, did not meet the primary or secondary endpoints in a recently
completed Phase 2 clinical study. The primary endpoint was the change in
pre-bronchodilator FEV1 (a measure of lung function) from baseline to dosing
completion at Week 8, comparing active doses to placebo. R343 was shown to be
relatively safe and well tolerated at both doses. In light of these overall
findings, the company has decided not to pursue this indication with R343.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in